Xcout Intel
ACES Diagnostics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to ACES Diagnostics, Inc. among diagnostics companies — ranked by similarity to what ACES Diagnostics, Inc. actually does, not by market-cap band.
Subscribe to see ACES Diagnostics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ACES Diagnostics, Inc.
ACES Diagnostics, Inc. has developed LymeSeek, a multiplexed Luminex-based immunoassay designed to provide accurate diagnostic solutions for Lyme disease.
ACES Diagnostics, Inc. at a glance
ACES Diagnostics, Inc. is a diagnostics company headquartered in United States. It has raised at least $4.4M across the 3 funding rounds on record. Its most recent funding round raised $400,000 in May 2026. Xcout tracks 12 named people at ACES Diagnostics, Inc., including Tammy Crawford (CEO).
ACES Diagnostics, Inc. leadership
- Tammy CrawfordCEO
- Glenn de SouzaChief Operating Officer
- Lisa StoneChief Financial Officer
- Jim KirkChief Development Officer
- Phillip StaffordChief Data Officer
- Tammy CrawfordFounder & Chief Executive Officer
6 more named people on record for ACES Diagnostics, Inc., with roles, board committees and tenure — see the full roster →
ACES Diagnostics, Inc. funding rounds
At least $4.4M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $400,000 | — | |
| Seed | $400,000 | 2 named | |
| SEC Form D filing | $3.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 ACES Diagnostics, Inc. competitors
Ranked by semantic similarity — how close each company is to ACES Diagnostics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar diagnostics company
Aces Diagnostics has developed LymeSeek, a multiplexed Luminex-based immunoassay designed to detect Lyme disease. The blood test is intended to improve early detection across all stages of the disease, though it is not yet FDA-approved or commercially available.
Similar diagnostics company
LumiraDx Ltd provides diagnostic products, specifically offering rapid microfluidic immunofluorescence assays such as the SARS-CoV-2 Ag test. These in vitro diagnostic tools are designed for near-patient and clinical settings to deliver rapid, lab-comparable health results.
Similar diagnostics company
Inflammatix, Inc. is a molecular diagnostics and biotechnology research company headquartered in Sunnyvale, California. It develops rapid point-of-care host-response diagnostic tests for suspected acute infections or sepsis.
Biotechnology
CyVek is a biotechnology and medical device company established in 2010 and headquartered in Wallingford, Connecticut. The company developed the CyPlex immunoassay technology, which integrates a microfluidic cartridge platform for measuring biological markers in the life sciences sector.
Biotechnology
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
Biotechnology
StabiLux Biosciences develops high-brightness dye technology utilizing boron nitride nanoparticles for biomedical applications. The company's platform supports antibodies, RNA, and proteins to help researchers detect biomarkers for early cancer detection, drug discovery, mRNA vaccines, and immunology.
Healthcare & Biotechnology
ImmunoProfile provides an at-home diagnostic testing system that evaluates an individual's antibody levels for eleven common, vaccine-preventable infectious diseases using a finger-prick blood sample. The company serves families, healthcare workers, students, travelers, and employers seeking to assess immunity status and identify potential gaps in protection.
Biotechnology
LeukoDx Inc., which officially changed its name to Accellix, Inc., provides fully automated, cost-effective, and actionable cell-based analysis available 24/7 at the point of need for a broad range of users.
Biotech
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
Biotechnology, Healthcare
Seegene provides molecular diagnostics products and technologies, including high-multiplex syndromic assays, automated instruments, and software systems. The company serves global healthcare and research partners by offering diagnostic solutions and a data platform for infectious disease detection and surveillance.
Healthcare & Biotechnology
Incite Health Life Sciences, Inc. is a CLIA-certified and CAP-accredited high-complexity clinical laboratory that provides specialized diagnostic testing, including pharmacogenomics, infectious disease screening, and immune system monitoring. The company serves physicians, medical institutions, employers, and clinical trials by utilizing advanced methodologies and data-driven approaches to support early detection, disease monitoring, and personalized medicine.
Similar diagnostics company
LymeAlert is pioneering early-detection technology for Lyme disease, designed to bring faster diagnosis and hope to millions affected by tick-borne illness. Operating in the public health sector, the private company is headquartered in Cambridge, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ACES Diagnostics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ACES Diagnostics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →